Emerging drugs to replace current leaders in first-line therapy for breast cancer

Michael C. Cox, Tu D. Dan, Sandra M. Swain

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Increasing knowledge of drug resistance and side effects of currently approved agents, and of the biology of breast cancer, has given way to new treatment options that improve on previously available agents, or medications that target specific kinases and proteins associated with an oncogenic phenotype. This paper discusses new agents, including improved formulations of paclitaxel and epothilones, and molecularly targeted agents such as bevacizumab, sunitinib malate, pertuzumab, lapatinib, the mTOR inhibitors and farnesyl transferase inhibitors. Although endocrine therapy is a targeted therapy, it is not covered in this paper. These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease.

Original languageEnglish (US)
Pages (from-to)489-501
Number of pages13
JournalExpert Opinion on Emerging Drugs
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2006

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
Epothilones
Therapeutics
Transferases
Paclitaxel
Drug-Related Side Effects and Adverse Reactions
Drug Resistance
Protein Kinases
Quality of Life
Phenotype

Keywords

  • Adjuvant therapy
  • Bevacizumab
  • Ixabepilone
  • Lapatinib
  • Pertuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs to replace current leaders in first-line therapy for breast cancer. / Cox, Michael C.; Dan, Tu D.; Swain, Sandra M.

In: Expert Opinion on Emerging Drugs, Vol. 11, No. 3, 01.09.2006, p. 489-501.

Research output: Contribution to journalReview article

@article{358df5bf33004435be6499b062e0eef5,
title = "Emerging drugs to replace current leaders in first-line therapy for breast cancer",
abstract = "Increasing knowledge of drug resistance and side effects of currently approved agents, and of the biology of breast cancer, has given way to new treatment options that improve on previously available agents, or medications that target specific kinases and proteins associated with an oncogenic phenotype. This paper discusses new agents, including improved formulations of paclitaxel and epothilones, and molecularly targeted agents such as bevacizumab, sunitinib malate, pertuzumab, lapatinib, the mTOR inhibitors and farnesyl transferase inhibitors. Although endocrine therapy is a targeted therapy, it is not covered in this paper. These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease.",
keywords = "Adjuvant therapy, Bevacizumab, Ixabepilone, Lapatinib, Pertuzumab",
author = "Cox, {Michael C.} and Dan, {Tu D.} and Swain, {Sandra M.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1517/14728214.11.3.489",
language = "English (US)",
volume = "11",
pages = "489--501",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging drugs to replace current leaders in first-line therapy for breast cancer

AU - Cox, Michael C.

AU - Dan, Tu D.

AU - Swain, Sandra M.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Increasing knowledge of drug resistance and side effects of currently approved agents, and of the biology of breast cancer, has given way to new treatment options that improve on previously available agents, or medications that target specific kinases and proteins associated with an oncogenic phenotype. This paper discusses new agents, including improved formulations of paclitaxel and epothilones, and molecularly targeted agents such as bevacizumab, sunitinib malate, pertuzumab, lapatinib, the mTOR inhibitors and farnesyl transferase inhibitors. Although endocrine therapy is a targeted therapy, it is not covered in this paper. These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease.

AB - Increasing knowledge of drug resistance and side effects of currently approved agents, and of the biology of breast cancer, has given way to new treatment options that improve on previously available agents, or medications that target specific kinases and proteins associated with an oncogenic phenotype. This paper discusses new agents, including improved formulations of paclitaxel and epothilones, and molecularly targeted agents such as bevacizumab, sunitinib malate, pertuzumab, lapatinib, the mTOR inhibitors and farnesyl transferase inhibitors. Although endocrine therapy is a targeted therapy, it is not covered in this paper. These agents have increased excitement in the treatment of breast cancer and stand on the forefront of a potential improvement in quality of life and treatment options for patients afflicted with this deadly disease.

KW - Adjuvant therapy

KW - Bevacizumab

KW - Ixabepilone

KW - Lapatinib

KW - Pertuzumab

UR - http://www.scopus.com/inward/record.url?scp=33748643613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748643613&partnerID=8YFLogxK

U2 - 10.1517/14728214.11.3.489

DO - 10.1517/14728214.11.3.489

M3 - Review article

VL - 11

SP - 489

EP - 501

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -